Regencell Bioscience (NASDAQ:RGC) Sees Large Volume Increase – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) saw unusually-high trading volume on Thursday . Approximately 245,923 shares changed hands during mid-day trading, a decline of 19% from the previous session’s volume of 304,867 shares.The stock last traded at $7.6750 and had previously closed at $8.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The business’s 50-day simple moving average is $20.90 and its two-hundred day simple moving average is $25.19.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Regencell Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of RGC. Bank of America Corp DE boosted its holdings in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after acquiring an additional 17,143 shares during the period. Amundi bought a new stake in shares of Regencell Bioscience during the 1st quarter valued at $219,000. Seven Fleet Capital Management LP bought a new stake in shares of Regencell Bioscience during the 4th quarter valued at $92,000. Vident Advisory LLC raised its stake in shares of Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the period. Finally, Hudson Bay Capital Management LP purchased a new stake in Regencell Bioscience during the 4th quarter worth about $275,000. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.